Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma.

Asthma Res Pract · 2022 · PMC9575249 · PMID 36253809

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

FE25–75% values showed a highly significant, gradual, and persistent increase (from 32.7 ± 18.2% at baseline to 48.6 ± 18.4% after 18 months).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.